Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid

Neuro-Oncology

Volumn 14, Issue 5, 2012, Pages 547-560

  M Saratsis, Amanda ^a,b   Yadavilli, Sridevi ^a,b   Magge, Suresh ^a,c   Rood, Brian R ^a,d   Perez, Jennifer ^a,d   Hill, D Ashley ^a,b,e,f   Hwang, Eugene ^a,d   Kilburn, Lindsay ^a,d   Packer, Roger J ^a,d   Nazarian, Javad ^a,b,f  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c Division of Neurosurgery   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e Childrens Oncology Group   (United States)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Brainstem glioma; CSF; CypA; DDAH1; DIPG

Indexed keywords

CYCLOPHILIN A; DIMETHYLARGININASE 1; HYDROLASE; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BRAIN STEM; BRAIN TISSUE; CANCER RECURRENCE; CARCINOGENESIS; CEREBROSPINAL FLUID ANALYSIS; CHILDHOOD CANCER; CONTROLLED STUDY; DATA BASE; GENOMICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LTQ ORBITRAP XL; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PARTEK GENOMICS SUITE; PONTINE GLIOMA; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEOIQ; PROTEOMICS; QUANTITATIVE ANALYSIS; SEQUEST ALGORITHM; STATISTICAL ANALYSIS; UPREGULATION; URINALYSIS; VALIDATION STUDY; WESTERN BLOTTING;

ADOLESCENT; AMIDOHYDROLASES; BLOTTING, WESTERN; BRAIN; BRAIN STEM NEOPLASMS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYCLOPHILINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; MALE; PONS; PONTINE GLIOMA; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860383781     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos067     Document Type: Article

References (63)

1. Walker DA, Punt JA, Sokal M. Clinical management of brain stem glioma. Arch Dis Child. 1999;80(6):558-564.
2. Berger MS, Edwards MS, LaMasters D, Davis RL, Wilson CB. Pediatric brain stem tumors: radiographic, pathological, and clinical correlations. Neurosurgery. 1983;12(3):298-302.
3. Albright AL, Price RA, Guthkelch AN. Brain stem gliomas of children. A clinicopathological study. Cancer. 1983;52(12):2313-2319.
4. Frazier JL, Lee J, Thomale UW, Noggle JC, Cohen KJ, Jallo GI. Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009;3(4):259-269.
5. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241-248.
6. Barkovich AJ, Krischer J, Kun LE, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg. 1990;16(2):73-83.
7. Epstein F. A staging system for brain stem gliomas. Cancer. 1985;56(7 Suppl):1804-1806.
8. Epstein F, McCleary EL. Intrinsic brain-stem tumors of childhood: surgical indications. Journal of Neurosurgery. 1986;64(1):11-15.
9. Fischbein NJ, Prados MD,WaraW, Russo C, Edwards MS, Barkovich AJ. Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr Neurosurg. 1996;24(1):9-23.
10. Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery. 1993;33(6):1026-1029; discussion 1029-1030.
11. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061-3068.
12. Bax DA, Mackay A, Little SE, et al. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2010;16(13):3368-3377.
13. Sharma S, Free A, Mei Y, Peiper SC, Wang Z, Cowell JK. Distinct molecular signatures in pediatric infratentorial glioblastomas defined by aCGH. Exp Mol Pathol. 2010;89(2):169-174.
14. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337-1344.
15. Barrow J, Adamowicz-Brice M, Cartmill M, et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13(2):212-222.
16. Gilbertson RJ, Hill DA, Hernan R, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9(10, pt 1):3620-3624.
17. Angelini P, Hawkins C, Laperriere N, Bouffet E, Bartels U. Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. J Neurooncol. 2011;101(1):75-81.
18. Rajagopal MU, Hathout Y, MacDonald TJ, et al. Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. Proteomics. 2011;11(5):935-943.
19. Ohnishi M, Matsumoto T, Nagashio R, et al. Proteomics of tumorspecific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein. Pathol Int. 2009;59(11):797-803.
20. Schuhmann MU, Zucht HD, Nassimi R, et al. Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol. 2010;36(2):201-207.
21. Leach PA, Estlin EJ, Coope DJ, Thorne JA, Kamaly-Asl ID. Diffuse brainstem gliomas in children: should we or shouldn't we biopsy? Br J Neurosurg. 2008;22(5):619-624.
22. Nazarian J, Santi M, Hathout Y, MacDonald TJ. Protein profiling of formalin fixed paraffin embedded tissue: Identification of potential biomarkers for pediatric brainstem glioma. Proteomics-Clinical Applications. 2008;2(6):915-924.
23. Jensen ON, Wilm M, Shevchenko A, Mann M. Sample preparation methods for mass spectrometric peptide mapping directly from 2-DE gels. Methods Mol Biol. 1999;112:513-530.
24. Berglund SR, Santana AR, Li D, Rice RH, Rocke DM, Goldberg Z. Proteomic analysis of low dose arsenic and ionizing radiation exposure on keratinocytes. Proteomics. 2009;9(7):1925-1938.
25. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. Molecular characterization of a case of atransferrinemia. Blood. 2000;96(13):4071-4074.
26. Hasegawa K,Wakino S, Tatematsu S, et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res. 2007;101(2): e2-e10.
27. Ito E, Obayashi S, Nagai A, Imamura M, Azuma H. Regulation of myometrial contractivity during pregnancy in the rat: potential role for DDAH. Mol Hum Reprod. 2009;15(8):507-512.
28. Richer S, Rudy D, Statkute L, Karofty K, Frankowski J. Serum iron, transferrin saturation, ferritin, and dietary data in age-related macular degeneration. Am J Ther. 2002;9(1):25-28.
29. Siemens N, Patenge N, Otto J, Fiedler T, Kreikemeyer B. Streptococcus pyogenes M49 plasminogen/plasmin binding facilitates keratinocyte invasion via integrin-integrin-linked kinase (ILK) pathways and protects from macrophage killing. J Biol Chem. 2011;286(24):21612-21622.
30. Tian X, Zhao C, Zhu H, et al. Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection. J Virol. 2010;84(7):3373-3381.
31. Wu M, Liu H, Fannin J, et al. Acetaminophen improves protein translational signaling in aged skeletal muscle. Rejuvenation Res. 2010;13(5):571-579.
32. Zakin MM. Regulation of transferrin gene expression. FASEB J. 1992;6(14):3253-3258.
33. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-oncology. 2012;14(1):29-33.
34. Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2008;26(1):96-105.
35. Shnaper S, Desbaillets I, Brown DA, et al. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer. 2009;125(11):2624-2630.
36. Khwaja FW, Reed MS, Olson JJ, et al. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res. 2007;6(2):559-570.
37. Hathout Y, Formolo CA, Brown KJ, Nazarian J. Current Proteome Profiling Methods. In: Bouchard, C, Hoffman, EP, eds. Encyclopaedia of Sports Medicine Genetic and Molecular Aspects of Sport Performance. Vol XVIII. Wiley-Blackwell; 2011:46-57.
38. Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR. Glioma pathophysiology: insights emerging from proteomics. Brain Pathology. 2010;20(4):691-703.
39. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006;12(24):7261-7270.
40. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170(5):1445-1453.
41. Suri V, Das P, Pathak P, et al. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro-oncology. 2009;11(3):274-280.
42. Wang P, Heitman J. The cyclophilins. Genome Biol. 2005;6(7):226.
43. Obchoei S, Wongkhan S, Wongkham C, Li M, Yao Q, Chen C. Cyclophilin A: potential functions and therapeutic target for human cancer. Med Sci Monit. 2009;15(11):RA221-RA232.
44. Han X, Yoon SH, Ding Y, et al. Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells. Oncol Rep. 2010;23(4):1053-1062.
45. Choi KJ, Piao YJ, Lim MJ, et al. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia-and cisplatin-induced cell death. Cancer Research. 2007;67(8):3654-3662.
46. Boulos S, Meloni BP, Arthur PG, Majda B, Bojarski C, Knuckey NW. Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis. 2007;25(1):54-64.
47. Jin ZG, Lungu AO, Xie L, Wang M, Wong C, Berk BC. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24(7):1186-1191.
48. Yurchenko V, Zybarth G, O'Connor M, et al. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. The Journal of Biological Chemistry. 2002;277(25):22959-22965.
49. Kim JY, Kim WJ, Kim H, Suk K, Lee WH. The Stimulation of CD147 Induces MMP-9 Expression through ERK and NF-kappaB in Macrophages: Implication for Atherosclerosis. Immune Netw. 2009;9(3):90-97.
50. Seko Y, Fujimura T, Taka H, Mineki R, Murayama K, Nagai R. Hypoxia followed by reoxygenation induces secretion of cyclophilin A from cultured rat cardiac myocytes. Biochemical and Biophysical Research Communications. 2004;317(1):162-168.
51. Tomita K, Izumi K, Okabe S. Roxatidine-and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci. 2003;93(3):321-330.
52. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69-82.
53. Gilbertson RJ, Gutmann DH. Tumorigenesis in the brain: location, location, location. Cancer Research. 2007;67(12):5579-5582.
54. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007; 7(10):733-736.
55. Monje M, Mitra SS, Freret ME, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA. 2011;108(11):4453-4458.
56. Hunt J, Cheng A, Hoyles A, Jervis E, Morshead CM. Cyclosporin A has direct effects on adult neural precursor cells. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 2010;30(8):2888-2896.
57. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2008;14(8):2378-2386.
58. Boult JK, Walker-Samue S, Jamin Y, Leiper JM, Whitley GS, Robinson SP. Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. J Pathol. 2011;225(3):344-352.
59. Kostourou V, Robinson SP, Whitley GS, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Research. 2003;63(16):4960-4966.
60. Kostourou V, Troy H, Murray JF, et al. Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo. Neoplasia. 2004;6(4):401-411.
61. Kostourou V, Robinson SP, Cartwright JE, Whitley GS. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer. 2002;87(6):673-680.
62. Tokuo H, Yunoue S, Feng L, et al. Phosphorylation of neurofibromin by cAMP-dependent protein kinase is regulated via a cellular association of N(G),N(G)-dimethylarginine dimethylaminohydrolase. FEBS Lett. 2001;494(1-2):48-53.
63. Breckenridge RA, Kelly P, Nandi M, Vallance PJ, Ohun TJ, Leiper J. A role for Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) in mammalian development. Int J Dev Biol. 2009; 54(1):215-220.